The Association of OLFM4 with the Progression and Cisplatin Resistance of Head and Neck Squamous Carcinoma
Current Oncology · 13.05.2025 · 32 (5) · 276
DOI: 10.3390/curroncol32050276 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 13.05.2025. Verfasst von Xinlu He und 5 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China. Hauptthemen laut MEDLINE: Cisplatin, Squamous Cell Carcinoma of Head and Neck, Drug Resistance, Neoplasm, Head and Neck Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, the Guangxi Natural Science Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Head and neck squamous cell carcinoma (HNSCC) is a highly prevalent malignant tumor globally with a poor prognosis. Despite continuous advancements in treatment modalities, the molecular mechanisms underlying its progression and chemotherapy resistance remain unclear. In previous studies, cisplatin drug induction was performed on HNSCC patient-derived tumor organoids (HNSCC-PDOs), successfully establishing a cisplatin-resistant organoid model (HNSCC-PDOcisR). This study conducted RNA sequencing on cisplatin-resistant HNSCC-PDOcisR and their parental PDOs. Bioinformatic analysis revealed that the oncoprotein olfactomedin 4 (OLFM4) was significantly upregulated in the drug-resistant model. Combined analysis of TCGA and CPTAC databases demonstrated that OLFM4 expression correlates with poor clinical prognosis in HNSCC. In vitro cellular experiments verified that OLFM4 overexpression significantly enhanced HNSCC cell proliferation, migration, and invasion capabilities (p < 0.05), while OLFM4 knockdown inhibited these phenotypes. Additionally, OLFM4 was found to mediate cisplatin resistance by regulating levels of reactive oxygen species (ROS), malondialdehyde (MDA), and ferrous ions (Fe2⁺), suppressing cisplatin-induced oxidative stress and ferroptosis while maintaining mitochondrial membrane potential. This study confirms that OLFM4 enhances tumor cell proliferation, migration, and resistance to cisplatin-induced cell death, thereby promoting HNSCC progression. These findings suggest OLFM4 may serve as a prognostic biomarker for HNSCC and a potential therapeutic target to reverse cisplatin resistance in HNSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China.
- Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry of Education, Nanning 530021, China.
- Life Sciences Institute of Guangxi Medical University, Nanning 530021, China.
ORCID-Profile: Xinlu He, Zhengbo Wei, Ying Xie
Förderung
- the National Natural Science Foundation of China
- the Guangxi Natural Science Foundation of China
- National Natural Science Foundation of China
- Guangxi Natural Science Foundation of China
- Guangxi Science and Technology Program
Zitieren
APA
He, X., Yao, X., Pang, K., Chen, X., Wei, Z., & Xie, Y. (2025). The Association of OLFM4 with the Progression and Cisplatin Resistance of Head and Neck Squamous Carcinoma. Current Oncology, 32(5), 276. https://doi.org/10.3390/curroncol32050276
Vancouver
He X, Yao X, Pang K, Chen X, Wei Z, Xie Y. The Association of OLFM4 with the Progression and Cisplatin Resistance of Head and Neck Squamous Carcinoma. Current Oncology. 2025;32(5):276. doi:10.3390/curroncol32050276
BibTeX
@article{He2025,
author = {He, Xinlu and Yao, Xi and Pang, Keling and Chen, Xulin and Wei, Zhengbo and Xie, Ying},
title = {The Association of OLFM4 with the Progression and Cisplatin Resistance of Head and Neck Squamous Carcinoma},
journal = {Current Oncology},
year = {2025},
volume = {32},
number = {5},
pages = {276},
doi = {10.3390/curroncol32050276}
}
EUVIMED